Why the study?
PDE5 inhibitors alter hemodynamic profiles, but their effects and safety in patients with concomitant valvular heart disease are not well documented.
Are phosphodiesterase-5 inhibitors safe to use in patients with valvular heart disease?
Are phosphodiesterase-5 inhibitors safe to use in patients with valvular heart disease?
This review analyzes the safety profile and hemodynamic effects of PDE5 inhibitors in patients with valvular heart disease.
Caution advised with PDE5 inhibitors in valvular heart disease; leaves open need for dedicated safety trials.
Erectile dysfunction is a common entity in clinical practice. Primary erectile dysfunction, not related to vasculopathy or psychiatric disorder, can be readily treated with phosphodiesterase inhibitors. These drugs have many physiologic effects that can alter a patient's hemodynamic profile considerably, especially in the presence of concomitant structural heart disease, specifically valvular heart disease. Although some contraindications to the use of PDE5 inhibitors in patients with cardiovascular disease are defined, the effect of these drugs in the presence of valvular heart disease is not well documented. The purpose of this review is to analyze the data regarding the safety of PDE5 inhibitors in patients with valvular heart disease.
No takes yet. Share an insight, caveat, or question.
Gopal et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: